AbbVie (incl. ImmunoGen, Capstan)
AbbVie owns Venclexta and Elahere, and bought Capstan, the leading in vivo CAR-T company.
Venetoclax, mirvetuximab (ImmunoGen, $10B), telisotuzumab vedotin (Emrelis, 2025), Temab-A (c-MET ADC), epcoritamab (with Genmab), Capstan CPTX2309 in vivo CAR-T (2025, up to $2.1B).
A pill that removes the survival shield from leukaemia cells, enabling chemotherapy-free, time-limited treatment for CLL.
Mirvetuximab soravtansine (Elahere) is the first ADC for ovarian cancer, for tumours with high folate receptor alpha.
Telisotuzumab vedotin (Emrelis) is the first c-MET-directed ADC, approved in 2025 for lung cancer with high c-MET protein.
Epcoritamab is an under-the-skin injection that pulls T cells onto lymphoma cells; it is approved for relapsed large B-cell and follicular lymphoma, and moving toward first line.
The pill that ended chemotherapy for most CLL. It blocks the survival signal B cells depend on, and it was the first drug to beat chemoimmunotherapy in nearly every CLL setting.
Leuprolide is the injectable that shuts off testosterone production, the foundation of hormone therapy for prostate cancer since the 1980s; it is also used for ovarian suppression in premenopausal breast cancer.
Pivekimab sunirine is an antibody-drug conjugate against CD123, approved in 2026 for blastic plasmacytoid dendritic cell neoplasm as the second targeted drug for this rare cancer.
Rovalpituzumab tesirine (Rova-T) was the first drug against DLL3 in small-cell lung cancer. AbbVie bought it for $5.8B and abandoned it after two failed phase 3 trials. The target later worked with a different weapon.
AMPLIFY delivered the first all-oral, fixed-duration doublet for front-line CLL and supported its approval, giving fit patients a way to avoid both chemotherapy and years of continuous BTK inhibitor. It does not settle whether a doublet or triplet is best, or how AV compares with venetoclax-obinutuzumab. Patients with TP53 aberration were excluded and still need different strategies.
CD20 x CD3 bispecifics gave patients whose lymphoma has failed CAR-T, or who cannot access it, an effective off-the-shelf treatment that can be started within days. Epcoritamab and glofitamab are now standard third-line options and are moving into earlier lines and combinations. They do not yet replace CAR-T, whose remissions appear more durable.
VIALE-A turned a palliative regimen into one that produces remission in two-thirds of older AML patients and is now the reference treatment for anyone not fit for intensive chemotherapy. It shifted the field towards lower-intensity targeted combinations and opened the door to adding FLT3, IDH and menin inhibitors to the backbone. Cure remains uncommon and most patients relapse within two years.
CLL14 established the first chemotherapy-free, fixed-duration regimen for front-line CLL and made MRD-guided thinking mainstream in the disease. Patients get a year of treatment and then a treatment-free period rather than indefinite therapy. The choice today is between fixed-duration venetoclax combinations and continuous BTK inhibitors, with no proven survival difference.
MURANO made fixed-duration venetoclax the standard for relapsed CLL and showed that stopping therapy after a deep response is safe for most patients. It also established MRD at end of treatment as a practical guide to who is likely to stay in remission. Retreatment with venetoclax at relapse appears feasible.
Pages like this
not linked directly; found by shared links- TargetBCL-2
Shares Walter and Eliza Hall Institute of Medical Research, Blastic plasmacytoid dendritic cell neoplasm (BPDCN), VIALE-A: venetoclax plus azacitidine for older adults with acute myeloid leukaemia who cannot have intensive chemotherapy, MURANO: two years of venetoclax plus rituximab versus chemo-immunotherapy in relapsed CLL.
- TargetCD20
Shares MURANO: two years of venetoclax plus rituximab versus chemo-immunotherapy in relapsed CLL, Epcoritamab, AMPLIFY: fixed-duration acalabrutinib plus venetoclax, with or without obinutuzumab, versus chemo-immunotherapy in fit CLL patients, CLL14: one year of venetoclax plus obinutuzumab instead of chemo-immunotherapy in older, less fit CLL patients.
- ProductBendamustine
Shares MURANO: two years of venetoclax plus rituximab versus chemo-immunotherapy in relapsed CLL, Waldenström macroglobulinaemia, Mantle cell lymphoma, Follicular lymphoma.
- CollectionLymphoma Research Foundation (LRF)
Shares Primary CNS lymphoma, Waldenström macroglobulinaemia, Mantle cell lymphoma, Follicular lymphoma.
- Termdel(17p) / TP53 aberration in CLL
Shares MURANO: two years of venetoclax plus rituximab versus chemo-immunotherapy in relapsed CLL, AMPLIFY: fixed-duration acalabrutinib plus venetoclax, with or without obinutuzumab, versus chemo-immunotherapy in fit CLL patients, CLL14: one year of venetoclax plus obinutuzumab instead of chemo-immunotherapy in older, less fit CLL patients, Mantle cell lymphoma.
- ProductRituximab
Shares MURANO: two years of venetoclax plus rituximab versus chemo-immunotherapy in relapsed CLL, Primary CNS lymphoma, Waldenström macroglobulinaemia, Mantle cell lymphoma.
- TrialCLL13 / GAIA
Shares AMPLIFY: fixed-duration acalabrutinib plus venetoclax, with or without obinutuzumab, versus chemo-immunotherapy in fit CLL patients, CLL14: one year of venetoclax plus obinutuzumab instead of chemo-immunotherapy in older, less fit CLL patients, Ibrutinib, Venetoclax.
- TargetCD123
Shares Pivekimab sunirine, Blastic plasmacytoid dendritic cell neoplasm (BPDCN), Acute myeloid leukaemia.